{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-IO2SKYBC/73631510-6682-429c-a98e-554622f5d441/PDF","dcterms:extent":"115 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-IO2SKYBC/cc4c421f-eeb9-4c75-b12a-d81f80012dec/TEXT","dcterms:extent":"41 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-IO2SKYBC","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2015","dc:creator":"Ferk, Polonca","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:66"},{"@xml:lang":"sl","#text":"str. 218-226"}],"dc:identifier":["ISSN:0014-8229","COBISSID:512498744","URN:URN:NBN:SI:doc-IO2SKYBC"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"dapoksetin"},{"@xml:lang":"en","#text":"dapoxetine"},{"@xml:lang":"en","#text":"erectile dysfunction"},{"@xml:lang":"sl","#text":"erektilna disfunkcija"},{"@xml:lang":"sl","#text":"farmakoterapija"},{"@xml:lang":"en","#text":"pharmacotherapy"},{"@xml:lang":"en","#text":"phosphodiesterase type 5 inhibitors"},{"@xml:lang":"en","#text":"premature ejaculation"},{"@xml:lang":"sl","#text":"prezgodnja ejakulacija"},{"@xml:lang":"sl","#text":"zaviralci fosfodiesteraze tipa 5"},{"@rdf:resource":"http://www.wikidata.org/entity/Q701216"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Zdravljenje erektilne disfunkcije in prezgodnje ejakulacije| Treatment of erectile dysfunction and premature ejaculation|"},"dc:description":[{"@xml:lang":"sl","#text":"Erectile dysfunction and premature ejaculation are the most common male sexual disorders and an increasing health problem in developed countries. Etiopathogenesis of the two disorders is multifactorial and includes several biological and psycological factors. Pharmacological, psychological and/or surgical treatment approaches depend on the type and severity of the disorder. Phosphodiesterase type 5 inhibitors are the drugs of choice in pharmacotherapy of erectile dysfunction. At present, dapoxetine, a short-acting selective serotonin reuptake inhibitor, is the only drug indicated to treat premature ejaculation. Several promising therapeutic approaches for treating male sexual dysfunction are being investigated, including stem cells and gene therapy"},{"@xml:lang":"sl","#text":"Erektilna disfunkcija in prezgodnja ejakulacija sta najpogostejši spolni motnji pri moških in naraščajoči zdravstveni problem v razvitem svetu. Etiopatogeneza obeh motenj je večfaktorska, kombinacija različnih bioloških in psiholoških dejavnikov. Zdravljenje je farmakološko, psihološko in/ali kirurško, odvisno od vrste in resnosti motnje. V farmakoterapiji erektilne disfunkcije so zdravila prvega izbora zaviralci fosfodiesteraze tipa 5. Prezgodnja ejakulacija je uradna indikacija le za dapoksetin, kratkodelujoči specifični zaviralec ponovnega privzema serotonina. Za zdravljenje spolne disfunkcije pri moškem so v razvoju obetavni terapevtski pristopi, vključno z zdravljenjem z zarodnimi celicami in genskim zdravljenjem"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-IO2SKYBC","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-IO2SKYBC"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-IO2SKYBC/73631510-6682-429c-a98e-554622f5d441/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-IO2SKYBC/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-IO2SKYBC"}}}}